ESMO 2024 preview – Summit and BioNTech battle again
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
The company dribbles out more data on IMA203, and the numbers head in the right direction.
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.